Compare CABR & CODX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CABR | CODX |
|---|---|---|
| Founded | 2020 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Package Goods/Cosmetics | Medical/Dental Instruments |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.2M | 15.6M |
| IPO Year | N/A | 2017 |
| Metric | CABR | CODX |
|---|---|---|
| Price | $0.90 | $0.18 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $2.25 |
| AVG Volume (30 Days) | 181.2K | ★ 1.6M |
| Earning Date | 03-20-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | $4,493.00 | ★ $507,892.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $18.89 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.06 | $0.22 |
| 52 Week High | $6.00 | $1.55 |
| Indicator | CABR | CODX |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 30.03 |
| Support Level | N/A | $0.22 |
| Resistance Level | N/A | $0.30 |
| Average True Range (ATR) | 0.00 | 0.03 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 0.00 | 2.05 |
Caring Brands Inc is a consumer wellness company specializing in over-the-counter (OTC) and cosmetic products.support health and wellness through the research and development of over-the-counter (OTC) products and intellectual property. It product pipeline addresses a range of conditions, including hair loss, eczema, burns, and sexual wellness. Company's majority of revenue is generated through the sales of OTC and consumer products and licensing royalties.
Co-Diagnostics Inc is a molecular diagnostics company. It develops, licenses, and commercializes molecular technologies such as lab systems (MDx device) and manufacture and sell reagents used for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). CDI's low-cost system uses its tests to diagnose tuberculosis, Zika, hepatitis B and C, Malaria, dengue and HIV.The Company's technologies are utilized for tests that are designed using the detection and/or analysis of nucleic acid molecules (DNA or RNA). The Company also uses its proprietary technology to design specific tests for its Co-Dx PCR platform and to locate genetic markers for use in applications other than infectious diseases.